Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine

被引：10

作者：

Monsonego, J. ^{[1
]}

Cortes, J. ^{[2
]}

Greppe, C. ^{[3
]}

Hampl, M. ^{[4
]}

Joura, E. ^{[5
]}

Singer, A. ^{[6
]}

机构：

[1] Federat Mutualiste Parisienne, Inst Cervix, F-75017 Paris, France

[2] Spanish Soc Obstet & Gynaecol, Palma de Mallorca 07004, Spain

[3] Sahlgrens Univ Hosp, Dept Obstet & Gynaecol, S-41345 Gothenburg, Sweden

[4] Univ Klinikum Dusseldorf, Dept Obstet & Gynaecol, Dusseldorf, Germany

[5] Med Univ Vienna, Dept Gynaecol, A-1090 Vienna, Austria

[6] Whittington Hosp, Dept Gynaecol, London N19 5NF, England

来源：

VACCINE | 2010年 / 28卷 / 51期

关键词：

Human papillomavirus; Vaccination; Young adult women; CERVICAL INTRAEPITHELIAL NEOPLASIA; POPULATION-BASED COHORT; NATURAL-HISTORY; PARTICLE VACCINE; HPV-VACCINATION; GENITAL WARTS; CANCER; PREVALENCE; EFFICACY; LESIONS;

D O I：

10.1016/j.vaccine.2010.10.017

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cervical cancer is a leading cause of cancer-related deaths worldwide. The causal role of human papillomavirus (HPV) infection in the pathogenesis of cervical cancer has prompted the development of vaccines against HPV. The highest risk of HPV infection is in women aged 16-25 years. Almost all young adult women can benefit from HPV vaccination. There is strong epidemiological and clinical support for vaccination programmes that target sexually active women in this age group to prevent HPV infection, and thus avert the development of HPV-related disease. Furthermore, the implementation of HPV vaccination programmes may benefit the development or awareness of cervical cancer prevention strategies and ultimately reduce the burden of cervical cancer and improve cervical cancer control. (c) 2010 Elsevier Ltd. All rights reserved.

引用

页码：8065 / 8072

页数：8

共 65 条

[1]

[Anonymous], 2008, GUID REP

[2]

[Anonymous], SEX TRANSM INF YOUNG

[3] Cervical cancer screening programmes and policies in 18 European countries [J].

Anttila, A ;

Ronco, G ;

Clifford, G ;

Bray, F ;

Hakama, M ;

Arbyn, M ;

Weiderpass, E .

BRITISH JOURNAL OF CANCER, 2004, 91 (05) :935-941

[4] Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis [J].

Arbyn, M. ;

Kyrgiou, M. ;

Simoens, C. ;

Raifu, A. O. ;

Koliopoulos, G. ;

Martin-Hirsch, P. ;

Prendiville, W. ;

Paraskevaidis, E. .

BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 (7673) :798-803

[5]

*AUSTR GOV DEP HLT, 2010, HUM PAP HPV INF HUM

[6] Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine [J].

Block, Stan L. ;

Brown, Darron R. ;

Chatterjee, Archana ;

Gold, Michael A. ;

Sings, Heather L. ;

Meibohm, Anne ;

Dana, Adrian ;

Haupt, Richard M. ;

Barr, Eliav ;

Tamms, Gretchen M. ;

Zhou, Haiping ;

Reisinger, Keith S. .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (02) :95-101

[7]

BURCHELL AN, 2001, VACCINE, pCH6

[8] Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection [J].

Carter, JJ ;

Koutsky, LA ;

Hughes, JP ;

Lee, SK ;

Kuypers, J ;

Kiviat, N ;

Galloway, DA .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :1911-1919

[9]

CASTELLSAGUE X, 2010, 26 INT PAP C CLIN WO

[10] Epidemiology and cost of treatment of genital warts in Spain [J].

Castellsague, Xavier ;

Cohet, Catherine ;

Puig-Tintore, Luis M. ;

Acebes, Luis Olmos ;

Salinas, Jesus ;

Martin, Maria San ;

Breitscheidel, Lusine ;

Remy, Vanessa .

EUROPEAN JOURNAL OF PUBLIC HEALTH, 2009, 19 (01) :106-110

← 1 2 3 4 5 6 7 →